Latest & greatest articles for folic acid

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on folic acid or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on folic acid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for folic acid

41. The effect of folic acid supplementation on insulin sensitivity and type 2 diabetes: a meta-analysis of randomized controlled trials

The effect of folic acid supplementation on insulin sensitivity and type 2 diabetes: a meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2016 PROSPERO

42. Pre-conception Folic Acid and Multivitamin Supplementation for the Primary and Secondary Prevention of Neural Tube Defects and Other Folic Acid-Sensitive Congenital Anomalies

Pre-conception Folic Acid and Multivitamin Supplementation for the Primary and Secondary Prevention of Neural Tube Defects and Other Folic Acid-Sensitive Congenital Anomalies Pre-conception Folic Acid and Multivitamin Supplementation for the Primary and Secondary Prevention of Neural Tube Defects and Other Folic Acid-Sensitive Congenital Anomalies - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 37, Issue 6, Pages 534 (...) –549 To read this article in full, please review your options for gaining access at the bottom of the page. Pre-conception Folic Acid and Multivitamin Supplementation for the Primary and Secondary Prevention of Neural Tube Defects and Other Folic Acid-Sensitive Congenital Anomalies PRINCIPAL AUTHOR, x R. Douglas Wilson , MD Calgary AB x GENETICS COMMITTEE x R. Douglas Wilson , MD (Chair) x R. Douglas Wilson , x François Audibert , MD x François Audibert , x Jo-Ann Brock , MD x Jo-Ann Brock , x June

2015 Society of Obstetricians and Gynaecologists of Canada

43. Efficacy of Folic Acid Therapy in Primary Prevention of Stroke Among Adults With Hypertension in China: The CSPPT Randomized Clinical Trial. Full Text available with Trip Pro

Efficacy of Folic Acid Therapy in Primary Prevention of Stroke Among Adults With Hypertension in China: The CSPPT Randomized Clinical Trial. Uncertainty remains about the efficacy of folic acid therapy for the primary prevention of stroke because of limited and inconsistent data.To test the primary hypothesis that therapy with enalapril and folic acid is more effective in reducing first stroke than enalapril alone among Chinese adults with hypertension.The China Stroke Primary Prevention Trial (...) , a randomized, double-blind clinical trial conducted from May 19, 2008, to August 24, 2013, in 32 communities in Jiangsu and Anhui provinces in China. A total of 20,702 adults with hypertension without history of stroke or myocardial infarction (MI) participated in the study.Eligible participants, stratified by MTHFR C677T genotypes (CC, CT, and TT), were randomly assigned to receive double-blind daily treatment with a single-pill combination containing enalapril, 10 mg, and folic acid, 0.8 mg (n = 10,348

2015 JAMA Controlled trial quality: predicted high

44. Folic acid supplementation for the prevention of preeclampsia

Folic acid supplementation for the prevention of preeclampsia Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing

2015 PROSPERO

45. Protocol for a systematic review to evaluate the evidence for an association between periconceptional folic acid exposure and twinning

Protocol for a systematic review to evaluate the evidence for an association between periconceptional folic acid exposure and twinning Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2015 PROSPERO

46. Pre-conception Folic Acid and Multivitamin Supplementation for the Primary and Secondary Prevention of Neural Tube Defects and Other Folic Acid-Sensitive Congenital Anomalies Full Text available with Trip Pro

Pre-conception Folic Acid and Multivitamin Supplementation for the Primary and Secondary Prevention of Neural Tube Defects and Other Folic Acid-Sensitive Congenital Anomalies Pre-conception Folic Acid and Multivitamin Supplementation for the Primary and Secondary Prevention of Neural Tube Defects and Other Folic Acid-Sensitive Congenital Anomalies - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 37, Issue 6, Pages 534 (...) –549 Pre-conception Folic Acid and Multivitamin Supplementation for the Primary and Secondary Prevention of Neural Tube Defects and Other Folic Acid-Sensitive Congenital Anomalies PRINCIPAL AUTHOR, x R. Douglas Wilson , MD Calgary AB x GENETICS COMMITTEE x R. Douglas Wilson , MD (Chair) x R. Douglas Wilson , x François Audibert , MD x François Audibert , x Jo-Ann Brock , MD x Jo-Ann Brock , x June Carroll , MD x June Carroll , x Lola Cartier , MSc x Lola Cartier , x Alain Gagnon , MD x Alain Gagnon

2015 Society of Obstetricians and Gynaecologists of Canada

47. Effect of Maternal Multiple Micronutrient vs Iron-Folic Acid Supplementation on Infant Mortality and Adverse Birth Outcomes in Rural Bangladesh: The JiVitA-3 Randomized Trial. Full Text available with Trip Pro

Effect of Maternal Multiple Micronutrient vs Iron-Folic Acid Supplementation on Infant Mortality and Adverse Birth Outcomes in Rural Bangladesh: The JiVitA-3 Randomized Trial. Maternal micronutrient deficiencies may adversely affect fetal and infant health, yet there is insufficient evidence of effects on these outcomes to guide antenatal micronutrient supplementation in South Asia.To assess effects of antenatal multiple micronutrient vs iron-folic acid supplementation on 6-month infant (...) -folic acid alone, taken daily from early pregnancy to 12 weeks postpartum.The primary outcome was all-cause infant mortality through 6 months (180 days). Prespecified secondary outcomes in this analysis included stillbirth, preterm birth (<37 weeks), and low birth weight (<2500 g). To maintain overall significance of α = .05, a Bonferroni-corrected α = .01 was calculated to evaluate statistical significance of primary and 4 secondary risk outcomes (.05/5).Among the 22,405 pregnancies in the multiple

2014 JAMA Controlled trial quality: predicted high

48. Folic Acid

Folic Acid USE OF FOLIC ACID IN PREGNANCY 0344 892 0909 USE OF FOLIC ACID IN PREGNANCY (Date of issue: February 2018 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Folic acid (pteroylglutamic acid/PGA) is a synthetic derivative (...) of the water-soluble form of vitamin B9 (also known as folate). It requires metabolism to dihydrofolic acid and then to its biologically active form tetrahydrofolate. Folate is necessary for the production of blood cells and DNA. Folic acid is used in the treatment of nutritional megaloblastic anaemias and prophylactically in individuals at risk of deficiency e.g. due to chronic haemolysis or renal dialysis. During pregnancy folate requirements are increased 5- to 10-fold and pregnant women are therefore

2014 UK Teratology Information Service

49. Completeness of reporting of setting and health worker cadre among trials on antenatal iron and folic acid supplementation in pregnancy: an assessment based on two Cochrane reviews. Full Text available with Trip Pro

Completeness of reporting of setting and health worker cadre among trials on antenatal iron and folic acid supplementation in pregnancy: an assessment based on two Cochrane reviews. Poor reporting of medical trials has triggered the development of trial reporting standards within the scientific community. In addition to a description of the proposed intervention, adequate information about the trial setting and the group of health workers (cadre) delivering the intervention would allow a better (...) understanding of the generalizability of the trial findings, facilitate replication of trial interventions and assist with assessment of trials for inclusion in systematic reviews. This study aims to determine the completeness of reporting for trial setting and cadre among trials included in two Cochrane reviews on iron and folic acid supplementation for women during pregnancy.From the 81 trials included in the two Cochrane reviews, we extracted data on the trial setting, including the facility type

2013 Systematic Reviews

50. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. (Abstract)

Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Methotrexate (MTX) is a disease modifying antirheumatic drug (DMARD) used as a first line agent for treating rheumatoid arthritis (RA). Pharmacologically, it is classified as an antimetabolite due to its antagonistic effect on folic acid metabolism. Many patients treated with MTX experience mucosal, gastrointestinal, hepatic or haematologic side effects. Supplementation with folic (...) or folinic acid during treatment with MTX may ameliorate these side effects.To identify trials of supplementation with folic acid or folinic acid during MTX therapy for rheumatoid arthritis and to assess the benefits and harms of folic acid and folinic acid (a) in reducing the mucosal, gastrointestinal (GI), hepatic and haematologic side effects of MTX, and (b) whether or not folic or folinic acid supplementation has any effect on MTX benefit.We originally performed MEDLINE searches, from January 1966

2013 Cochrane

51. Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50 000 individuals Full Text available with Trip Pro

Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50 000 individuals Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50 000 individuals Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50 000 individuals Vollset SE, Clarke R (...) , Lewington S, Ebbing M, Halsey J, Lonn E, Armitage J, Manson JA, Hankey GJ, Spence JD, Galan P, Bonaa KH, Jamison R, Gaziano JM, Guarino P, Baron JA, Logan RF, Giovannucci EL, den Heijer M, Ueland PM, Bennett D, Collins R, Peto R; B-Vitamin Treatment Trialists' Collaboration CRD summary The review concluded that folic acid supplementation did not substantially increase or decrease incidence of site-specific cancer during the first five years of treatment. These conclusions represent a fair reflection

2013 DARE.

52. Association between maternal use of folic acid supplements and risk of autism spectrum disorders in children. Full Text available with Trip Pro

Association between maternal use of folic acid supplements and risk of autism spectrum disorders in children. Prenatal folic acid supplements reduce the risk of neural tube defects in children, but it has not been determined whether they protect against other neurodevelopmental disorders.To examine the association between maternal use of prenatal folic acid supplements and subsequent risk of autism spectrum disorders (ASDs) (autistic disorder, Asperger syndrome, pervasive developmental disorder (...) -not otherwise specified [PDD-NOS]) in children.The study sample of 85,176 children was derived from the population-based, prospective Norwegian Mother and Child Cohort Study (MoBa). The children were born in 2002-2008; by the end of follow-up on March 31, 2012, the age range was 3.3 through 10.2 years (mean, 6.4 years). The exposure of primary interest was use of folic acid from 4 weeks before to 8 weeks after the start of pregnancy, defined as the first day of the last menstrual period before conception

2013 JAMA

53. Cancer risk with folic acid supplements: a systematic review and meta-analysis

Cancer risk with folic acid supplements: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 DARE.

54. Cohort study: Maternal folic acid supplements associated with reduced autism risk in the child Full Text available with Trip Pro

Cohort study: Maternal folic acid supplements associated with reduced autism risk in the child Maternal folic acid supplements associated with reduced autism risk in the child | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Maternal folic acid supplements associated with reduced autism risk in the child Article Text Aetiology Cohort study Maternal folic acid supplements associated with reduced autism risk in the child Rebecca J Schmidt

2013 Evidence-Based Medicine

55. The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis

The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis Jardine MJ, Kang A, Zoungas S, Navaneethan SD, Ninomiya T (...) , Nigwekar SU, Gallagher MP, Cass A, Strippoli G, Perkovic V CRD summary The authors concluded that folic acid based homocysteine lowering therapy did not reduce cardiovascular events in people with kidney disease, and should not be used as a preventive treatment. Overall, this was a well-conducted review and the conclusion is likely to be reliable. Authors' objectives To evaluate the effect of folic acid based homocysteine lowering on cardiovascular outcomes in people with kidney disease. Searching

2012 DARE.

56. Bias toward the null hypothesis in pregnancy drug studies that do not include data on medical terminations of pregnancy: the folic acid antagonists (Abstract)

Bias toward the null hypothesis in pregnancy drug studies that do not include data on medical terminations of pregnancy: the folic acid antagonists Most studies on safety/risk of drugs in pregnancy consider the proportion of births (but not pregnancy terminations) affected by the drug from all exposed infants. Lack of data on pregnancy terminations could bias results. A computerized database for medications dispensed to pregnant women in southern Israel was linked with records from the district (...) hospital; 84 823 deliveries and 998 medical pregnancy terminations took place; 571 of the women were exposed to folic acid antagonists in the first trimester. When only births were examined, there was no association between folic acid antagonists and fetal malformations. When data on pregnancy terminations were examined and births and pregnancy terminations were combined, there was a significant risk (neural tube defects: odds ratio 18.83, 95% confidence interval 9.24-38.37; cardiovascular defects

2012 EvidenceUpdates

57. Intermittent iron and folic acid supplementation in non-anaemic pregnant women

Intermittent iron and folic acid supplementation in non-anaemic pregnant women WHO | Archived: Intermittent iron and folic acid supplementation in non-anaemic pregnant women Archived This publication and its contents has been superseded by a more recent version. It is here for reference purposes. Please follow WHO Regional websites Access Nutrition Menu Archived: Intermittent iron and folic acid supplementation in non-anaemic pregnant women Guideline Authors : World Health Organization (...) Publication details Number of pages : 26 Publication date : 2012 Languages : English, Farsi, Portuguese, Spanish ISBN : 978 92 4 150201 6 Downloads pdf, 1.20Mb pdf, 661.67kb pdf, 807kb Overview This guideline provides global, evidence-informed recommendations on intermittent iron and folic acid supplementation as a public health intervention for the purpose of improving pregnancy outcomes and reducing maternal anaemia in pregnancy. The guideline will help Member States and their partners in their efforts

2012 World Health Organisation Guidelines

58. Daily iron and folic acid supplementation in pregnant women

Daily iron and folic acid supplementation in pregnant women WHO | Archived: Daily iron and folic acid supplementation in pregnant women Archived This publication and its contents has been superseded by a more recent version. It is here for reference purposes. Please follow WHO Regional websites Access Nutrition Menu Archived: Daily iron and folic acid supplementation in pregnant women Guideline Authors : World Health Organization Publication details Number of pages : 27 Publication date : 2012 (...) Languages : English, Portuguese, Spanish ISBN : 978 92 4 150199 6 Downloads pdf, 1.045Mb pdf, 862.5kb Overview This guideline provides global, evidence-informed recommendations on daily iron and folic acid supplementation in pregnant women as a public health intervention for the purpose of improving pregnancy outcomes and reducing maternal anaemia in pregnancy. The guideline will help Members States and their partners in their efforts to make informed decisions on the appropriate nutrition actions

2012 World Health Organisation Guidelines

59. Efficacy of folic acid supplementation in stroke prevention: new insight from a meta-analysis

Efficacy of folic acid supplementation in stroke prevention: new insight from a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

60. The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis. Full Text available with Trip Pro

The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis. To systematically review the effect of folic acid based homocysteine lowering on cardiovascular outcomes in people with kidney disease.Systematic review and meta-analysis.Medline, Embase, the Cochrane Library, and ClinicalTrials.gov to June 2011.Randomised trials in people with non-dialysis dependent chronic kidney disease or end stage kidney disease (...) or with a functioning kidney transplant reporting at least 100 patient years of follow-up and assessing the effect of folic acid based homocysteine lowering therapy. No language restrictions were applied.Two reviewers independently extracted data on study setting, design, and outcomes using a standardised form. The primary endpoint was cardiovascular events (myocardial infarction, stroke, and cardiovascular mortality, or as defined by study author). Secondary endpoints included the individual composite components

2012 BMJ